Výsledky vyhledávání - "Tiffany, Ossi"

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor

Autor: Francesco Franchi, Luis Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Birgit Reiter, Bernd Jilma, Dominick J. Angiolillo

Publikováno v: JACC: Cardiovascular Interventions. 16:36-46

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ae1c32ce9d4043d8a671307c066d429
https://doi.org/10.1016/j.jcin.2022.10.034

Zobrazit plný text záznamu

Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban

Autor: Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda Maldonado, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick Angiolillo

Publikováno v: Thrombosis and Haemostasis.

Background:To date, there is no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen. Objectives: To assess the feasibility of switching from DAPT to DPI and t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::538f150e1e47420b9595f99e0422a6b2
https://doi.org/10.1055/a-2098-6639

Zobrazit plný text záznamu

1156 CANGRELOR IN PATIENTS WITH CORONARY ARTERY DISEASE PRE-TREATED WITH TICAGRELOR: THE SWITCHING ANTIPLATELET (SWAP)-5 STUDY

Autor: Salvatore Giordano, Francesco Franchi, Luis Ortega-paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Birgit Reiter, Bernd Jilma, Dominick J Angiolillo

Publikováno v: European Heart Journal Supplements. 24

Objectives To rule out a drug-drug interaction (DDI) among cangrelor-treated patients who have been pre-treated with ticagrelor. Background There are no studies specifically designed to rule out a DDI when cangrelor is used among patients who have be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2aab1151f1df482f2bd586f53b4ebe3
https://doi.org/10.1093/eurheartjsupp/suac121.769

Zobrazit plný text záznamu

1157 WITCHING FROM DUAL ANTIPLATELET THERAPY WITH ASPIRIN PLUS A P2Y12 INHIBITOR TO DUAL PATHWAY INHIBITION WITH ASPIRIN PLUS VASCULAR-DOSE RIVAROXABAN: THE SWITCHING ANTI-PLATELET AND ANTI-COAGULANT THERAPY (SWAP-AC) STUDY

Autor: Salvatore Giordano, Luis Ortega-paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick J. Angiolillo

Publikováno v: European Heart Journal Supplements. 24

Aims To assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and to compare the pharmacodynamic (PD) profiles of these treatment regimens. Methods and results This was a prospective, randomized, P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8473e5fdb5ba45c362300bd9a82fea0
https://doi.org/10.1093/eurheartjsupp/suac121.768

Zobrazit plný text záznamu

Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study

Autor: Francesco, Franchi, Luis, Ortega-Paz, Fabiana, Rollini, Mattia, Galli, Latonya, Been, Ghussan, Ghanem, Awss, Shalhoub, Tiffany, Ossi, Andrea, Rivas, Xuan, Zhou, Andres M, Pineda, Siva, Suryadevara, Daniel, Soffer, Martin M, Zenni, Dominick J, Angiolillo

Publikováno v: JACC. Cardiovascular interventions.

To rule out a drug-drug interaction (DDI) among cangrelor-treated patients who have been pre-treated with ticagrelor.There are no studies specifically designed to rule out a DDI when cangrelor is used among patients who have been pre-treated with tic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7ba1ab6e7a5c9da5dfbcabc06b681a41
https://pubmed.ncbi.nlm.nih.gov/36317958

Zobrazit plný text záznamu

Akademický článek

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.

Autor: Ortega-Paz, Luis, Franchi, Francesco, Rollini, Fabiana, Galli, Mattia, Been, Latonya, Ghanem, Ghussan, Shalhoub, Awss, Ossi, Tiffany, Rivas, Andrea, Zhou, Xuan, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Jennings, Lisa K., Angiolillo, Dominick J.

Publikováno v: Thrombosis & Haemostasis; Mar2024, Vol. 124 Issue 3, p263-273, 11p

Zobrazit plný text záznamu

Periodical

Reports Summarize Heart Disease Study Results from University of Florida [Cangrelor In Patients With Coronary Artery Disease Pretreated With Ticagrelor the Switching Antiplatelet (Swap)-5 Study].

Publikováno v: Heart Disease Weekly; 8/21/2023, p567-567, 1p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání